Literature DB >> 26011027

Development and analysis of furazolidone-resistant Escherichia coli mutants.

Sandra Martínez-Puchol1, Cláudia Gomes1, Maria J Pons1, Lidia Ruiz-Roldán1, Alba Torrents de la Peña1, Theresa J Ochoa2,3, Joaquim Ruiz1.   

Abstract

Furazolidone-resistant mutants were obtained from four clinical isolates of diarrhoeagenic Escherichia coli. The stability of the resistance and the frequency of mutation were established. The minimal inhibitory concentration of furazolidone, nitrofurantoin, nalidixic acid, ampicillin, chloramphenicol and tetracycline was established both in the presence and absence of the efflux pump inhibitor Phe-Arg-β-Naphtylamyde. The presence of mutations in the nitroreductase genes nfsA and nfsB was analysed by PCR; sequencing and their enzymatic activity was assessed by a spectrophotometric assay. Alterations in outer membrane proteins were studied by SDS-PAGE. The frequency of mutation ranged from <9.6 × 10(-10) to 9.59 × 10(-7) . Neither an effect on efflux pumps inhibited by Phe-Arg-β-Naphtylamyde nor cross-resistance with the antibiotics studied was observed. Nineteen mutants (52.94%) presented mutations in the nitroreductase-encoding genes: 17 in the nfsA gene (15 mutants with an internal stop codon, 2 with amino acid changes), 2 in the nfsB (all amino acid changes). Alterations in the outer membrane proteins OmpA and OmpW were also observed. Although more studies are necessary to find other resistance mechanisms, present data showed the low potential of selecting furazolidone-resistant mutants, together with the lack of cross-resistance with unrelated antimicrobial agents.
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Enterobacteriaceae; Nitrofuran; resistance mechanisms

Mesh:

Substances:

Year:  2015        PMID: 26011027     DOI: 10.1111/apm.12401

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  4 in total

1.  Comparative analysis of antimicrobial resistance in enterotoxigenic Escherichia coli isolates from two paediatric cohort studies in Lima, Peru.

Authors:  Anicia M Medina; Fulton P Rivera; Maria J Pons; Maribel Riveros; Cláudia Gomes; María Bernal; Rina Meza; Ryan C Maves; Luis Huicho; Elsa Chea-Woo; Claudio F Lanata; Ana I Gil; Theresa J Ochoa; Joaquim Ruiz
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-08       Impact factor: 2.184

2.  Novel 5-Nitrofuran-Activating Reductase in Escherichia coli.

Authors:  Vuong Van Hung Le; Ieuan G Davies; Christina D Moon; David Wheeler; Patrick J Biggs; Jasna Rakonjac
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Alanine Enhances Aminoglycosides-Induced ROS Production as Revealed by Proteomic Analysis.

Authors:  Jin-Zhou Ye; Yu-Bin Su; Xiang-Min Lin; Shi-Shi Lai; Wan-Xin Li; Farman Ali; Jun Zheng; Bo Peng
Journal:  Front Microbiol       Date:  2018-01-30       Impact factor: 5.640

4.  In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria.

Authors:  Vuong Van Hung Le; Catrina Olivera; Julian Spagnuolo; Ieuan G Davies; Jasna Rakonjac
Journal:  BMC Microbiol       Date:  2020-01-06       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.